Drug repurposing rescue and repositioning // Drug Repurposing

Drug repurposing rescue and repositioning

We are a service provider company working on our Personalized Drug Rescue and Repositioning software suite, which unifies data fusion and biomarker selection technologies in a sequential decision theoretic framework. Our aim is to support the identification of novel indications or novel contexts for failed candidates and to extend the life-cycle of marketed drugs.

Drug repositioning is a traditional technique, which was mainly guided by serendipitous observations for decades. The following factors all contribute to its recent popularity: success stories, the productivity gap, a shortened pharma pipeline, polypharmacy (multiple targets for a given drug), network pharmacology (multiple factors, pathways behind diseases), and improved in silico data integration and fusion methodologies.

Pharmacogenetics is a similarly well-known concept for decades, but recent dramatic improvements in molecular biological measurement technologies revolutionized this area leading to the concepts of pharmacogenomics and personalized medicine. The personal genome combined with improved electronic health records using more refined phenotypical descriptors for the disease, efficacy, and side-effects opens up new possibilities for the development of niche-drugs. Besides cost-effective measurements, the improved biomarker selection and population stratification methods coping with interactions, temporality, and interventions, and also supporting functional and pathway level interpretation are equally crucial to reach these goals.

We have developed our Personalized Drug Rescue and Repositioning software suite, to cope with these two challenges and to utilize their synergy, which unifies systems-based biomarker analysis and similarity-based data fusion technologies in a sequential decision theoretic framework.

You might also like

Nature editorial: Repurposing drugs

by Drosophila3


Nature 465, 267–268 (20 May 2010) doi:10.1038/465267b
Published online 19 May 2010
The United States should protect investments used to find new uses for old drugs.
In 2007, a paper in the journal Cancer Cell announced that the compound dichloroacetate (DCA) had been found to shrink tumours in rats (S. Bonnet et al. Cancer Cell 11, 37–51; 2007). That news by itself would not have created much of a stir: many compounds tested in rodents raise hopes of their becoming potential cures, and almost as many go on to fail in human clinical trials

Scribner Sex, Drugs, and Cocoa Puffs: A Low Culture Manifesto
Book (Scribner)

Cancer-Fighting Patch to Treat Mouth Cancer  — Drug Discovery & Development
Ohio State, through the Ohio State Innovation Foundation and the university's Drug Development Institute, and the University of Michigan licensed the intellectual property to the newly formed Sirona Therapeutics.

Little, Brown and Company Portrait of an Addict as a Young Man: A Memoir
Book (Little, Brown and Company)
Vintage Fear and Loathing in Las Vegas: A Savage Journey to the Heart of the American Dream
Book (Vintage)
Spiegel & Grau Big Machine: A Novel
Book (Spiegel & Grau)
W. W. Norton & Company Trainspotting
Book (W. W. Norton & Company)